Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Somovilla Crespo, Beatriz ^a   Alfonso Pérez, Manuel ^a,b   Cuesta Mateos, Carlos ^a,b   Carballo De Dios, Cristina ^a   Beltrán, Amada E ^a   Terrón, Fernando ^b   Pérez Villar, Juan J ^b   Gamallo Amat, Carlos ^a   Pérez Chacón, Gema ^c   Fernández Ruiz, Elena ^a   Zapata, Juan M ^c   Muñoz Calleja, Cecilia ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b Immunological and Medicinal Products SL   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CCR7; IMMUNOMODULATING AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CCR7; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION; CENTRAL NERVOUS SYSTEM; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LUNG; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; SKIN LYMPHOMA; SPLEEN; TARGET CELL DESTRUCTION; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, MANTLE-CELL; MICE; MICE, INBRED NOD; MICE, SCID; RECEPTORS, CCR7; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888782000     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-89     Document Type: Article

References (46)

1. Lymphoma dissemination: the other face of lymphocyte homing. Pals ST, de Gorter DJ, Spaargaren M, Blood 2007 110 3102 3111 (Pubitemid 350106300)
2. Homeostatic chemokine receptors and organ-specific metastasis. Zlotnik A, Burkhardt AM, Homey B, Nat Rev Immunol 2011 11 597 606
3. Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs. Hopken UE, Rehm A, J Mol Med (Berl) 2012 90 1237 1245
4. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Steidl C, Connors JM, Gascoyne RD, J Clin Oncol 2011 29 1812 1826
5. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F, Blood 2009 114 3367 3375
6. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Burger JA, Montserrat E, Blood 2013 121 1501 1509
7. Homing and cellular traffic in lymph nodes. von Andrian UH, Mempel TR, Nat Rev Immunol 2003 3 867 878 (Pubitemid 37411716)
8. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Ley K, Laudanna C, Cybulsky MI, Nourshargh S, Nat Rev Immunol 2007 7 678 689 (Pubitemid 47327397)
9. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Forster R, Schubel A, Breitfeld D, Kremmer E, Renner-Muller I, Wolf E, Lipp M, Cell 1999 99 23 33 (Pubitemid 29468627)
10. Orchestrating the orchestrators: chemokines in control of T cell traffic. Bromley SK, Mempel TR, Luster AD, Nat Immunol 2008 9 970 980
11. Lymph node B lymphocyte trafficking is constrained by anatomy and highly dependent upon chemoattractant desensitization. Park C, Hwang IY, Sinha RK, Kamenyeva O, Davis MD, Kehrl JH, Blood 2012 119 978 989
12. Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. Lopez-Giral S, Quintana NE, Cabrerizo M, Alfonso-Perez M, Sala-Valdes M, De Soria VG, Fernandez-Ranada JM, Fernandez-Ruiz E, Munoz C, J Leukoc Biol 2004 76 462 471 (Pubitemid 39006961)
13. The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. Till KJ, Lin K, Zuzel M, Cawley JC, Blood 2002 99 2977 2984 (Pubitemid 34525388)
14. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, et al. Blood 2004 104 502 508 (Pubitemid 38900034)
15. Effect of chemokine receptors CCR7 on disseminated behavior of human T cell lymphoma: clinical and experimental study. Yang J, Wang S, Zhao G, Sun B, J Exp Clin Cancer Res 2011 30 51
16. Expression of the chemokine receptors CXCR4, CXCR5, and CCR7 in primary central nervous system lymphoma. Jahnke K, Coupland SE, Na IK, Loddenkemper C, Keilholz U, Korfel A, Stein H, Thiel E, Scheibenbogen C, Blood 2005 106 384 385 (Pubitemid 40967218)
17. The chemokine system and cancer. Balkwill FR, J Pathol 2012 226 148 157
18. CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Buonamici S, Trimarchi T, Ruocco MG, Reavie L, Cathelin S, Mar BG, Klinakis A, Lukyanov Y, Tseng JC, Sen F, et al. Nature 2009 459 1000 1004
19. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. Alfonso-Perez M, Lopez-Giral S, Quintana NE, Loscertales J, Martin-Jimenez P, Munoz C, J Leukoc Biol 2006 79 1157 1165 (Pubitemid 44835549)
20. Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia. Cuesta-Mateos C, Lopez-Giral S, Alfonso-Perez M, de Soria VG, Loscertales J, Guasch-Vidal S, Beltran AE, Zapata JM, Munoz-Calleja C, Exp Hematol 2010 38 756 764
21. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Perez-Galan P, Dreyling M, Wiestner A, Blood 2011 117 26 38
22. Novel targeted therapies for mantle cell lymphoma. Alinari L, Christian B, Baiocchi RA, Oncotarget 2012 3 203 211
23. Molecular pathogenesis of mantle cell lymphoma. Jares P, Colomer D, Campo E, J Clin Invest 2012 122 3416 3423
24. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, et al. Ann Oncol 2008 19 1327 1330 (Pubitemid 351911966)
25. Improvement of overall survival in advanced stage mantle cell lymphoma. Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, et al. J Clin Oncol 2009 27 511 518
26. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell Non-hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES, Rodeghiero F, J Clin Oncol 2013 31 11 1442 1449
27. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. Schulz H, Bohlius JF, Trelle S, Skoetz N, Reiser M, Kober T, Schwarzer G, Herold M, Dreyling M, Hallek M, Engert A, J Natl Cancer Inst 2007 99 706 714 (Pubitemid 47078732)
28. Matrix metalloproteinase-9 is up-regulated by CCL21/CCR7 interaction via extracellular signal-regulated kinase-1/2 signaling and is involved in CCL21-driven B-cell chronic lymphocytic leukemia cell invasion and migration. Redondo-Munoz J, Jose Terol M, Garcia-Marco JA, Garcia-Pardo A, Blood 2008 111 383 386
29. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL, Oncogene 2005 24 5897 5904 (Pubitemid 43080081)
30. Homeostatic chemokines increase survival of B-chronic lymphocytic leukemia cells through inactivation of transcription factor FOXO3a. Ticchioni M, Essafi M, Jeandel PY, Davi F, Cassuto JP, Deckert M, Bernard A, Oncogene 2007 26 7081 7091 (Pubitemid 350064189)
31. CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. Xu Y, Liu L, Qiu X, Liu Z, Li H, Li Z, Luo W, Wang E, PLoS One 2012 7 33262
32. Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Rehm A, Mensen A, Schradi K, Gerlach K, Wittstock S, Winter S, Buchner G, Dorken B, Lipp M, Hopken UE, Blood 2011 118 1020 1033
33. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK, Sprague K, Van Etten RA, Kuliopulos A, Covic L, Blood 2012 119 1717 1725
34. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M, Blood 2012 119 2590 2594
35. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K, Blood 2010 115 4497 4506
36. Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Zhang S, Wu CC, Fecteau JF, Cui B, Chen L, Zhang L, Wu R, Rassenti L, Lao F, Weigand S, Kipps TJ, Proc Natl Acad Sci USA 2013 110 15 6127 6132
37. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Hu Y, Gale M, Shields J, Garron C, Swistak M, Nguyen TH, Jacques G, Fogle R, Siders W, Kaplan J, Leuk Lymphoma 2012 53 130 138
38. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, Pedron S, Parisi A, Ren J, Cecconi D, et al. Cell Oncol (Dordr) 2011 34 141 153
39. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, Siders WM, Kaplan JM, Immunology 2009 128 260 270
40. Mechanisms of action of CD20 antibodies. Boross P, Leusen JH, Am J Cancer Res 2013 2 676 690
41. Lymph node homing of T cells and dendritic cells via afferent lymphatics. Forster R, Braun A, Worbs T, Trends Immunol 2012 33 6 271 280
42. CCR7 and its ligands: balancing immunity and tolerance. Forster R, Davalos-Misslitz AC, Rot A, Nat Rev Immunol 2008 8 362 371 (Pubitemid 351595218)
43. Manifestation of spontaneous and early autoimmune gastritis in CCR7-deficient mice. Winter S, Rehm A, Wichner K, Scheel T, Batra A, Siegmund B, Berek C, Lipp M, Hopken UE, Am J Pathol 2011 179 754 765
44. Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma-targets for therapeutic intervention? Johrer K, Hofbauer SW, Zelle-Rieser C, Greil R, Hartmann TN, Expert Opin Biol Ther 2012 12 425 441
45. Chemokines in health and disease. Raman D, Sobolik-Delmaire T, Richmond A, Exp Cell Res 2011 317 575 589
46. CCR7 mediates directed growth of melanomas towards lymphatics. Emmett MS, Lanati S, Dunn DB, Stone OA, Bates DO, Microcirculation 2011 18 172 182